🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 100% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Capsule(s) Serving Size
60 Servings
Vitamin Product Type
100% Evidence Coverage

Supplement Facts — Evidence Check

45 mcg
✅ Within RDA (0.4× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.045mg

Other Ingredients

Microcrystalline Cellulose Hypromellose Water Stearic Acid Magnesium Stearate Silica

Label Claims — Verification

Nutrient
All Other
Structure/Function
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Vegan Vegetarian Adult (18 - 50 Years) No Allergies Gluten Free Dairy Free

Product Information

📋 Directions for Use

Directions: Take one capsule with a meal, one to two times daily, or as directed by your healthcare professional.

⚠️ Warnings & Precautions

Consult your healthcare professional prior to use.

Individuals taking blood thinners or other medication should discuss potential interactions with their healthcare professional.

Do not use if tamper seal is damaged.

Storage: Keep closed in a cool, dry place out of reach of children.

🧪 Formulation Notes

K2-45, derived from non-GMO soybeans fermented with Bacillus subtilis natto, is the most bioavailable and bioactive form of supplemental vitamin K2 available. Historical use and numerous studies have confirmed safety and efficacy for bone and heart health.

Formulated to exclude: Wheat, gluten, yeast, soy protein, animal and dairy products, fish, shellfish, peanuts, tree nuts, egg, sesame, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, and artificial preservatives.

Natural Vitamin K2 as MK-7

Vegetarian caps

Additional Information

Storage: Keep closed in a cool, dry place out of reach of children.

ePV (ePedigree Verification)

Third-Party Verified GMP Compliant

Scan to learn more! This package is completely recyclable

Product Details

UPC / SKU 8 71149 00317 3
DSLD Entry Date 2024-12-21
Product Type Vitamin
Form Capsule
Brand XYMOGEN
DSLD ID 303712
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →